Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 56 132 sessions, September 5, 2025 to September 11, 2026
- Largest daily move
- +99900% close of March 18, 2026
- 1-year change
- +1431718.2% closing prices, September 5, 2025 to September 11, 2026
- 5-year change
- -97.9% closing prices, September 10, 2021 to September 11, 2026
Company Description
Eloxx Pharmaceuticals (NASDAQ: ELOX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $54.0M.
ELOX has gained 1431718.2% over the past year. The last closing price was $15.75.
For FY2025, Eloxx Pharmaceuticals reported revenue of $0 with net income of -$6.0M and diluted earnings per share of -$5.34.
This page collects what Stock Titan holds for ELOX, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Eloxx Pharmaceuticals (ELOX) closed at $15.75 on September 11, 2026. Over the past 12 months, the price has gained 1431718.2%.
ELOX Metrics & Rankings
Price returns through September 11, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Eloxx Pharmaceuticals has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, offering, management, clinical trial. View all ELOX news →
SEC Filings
Eloxx Pharmaceuticals has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G, 1 Form S-1, 1 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on September 11, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ELOX SEC filings →
Financial Highlights
operating income reached -$6.4M, and net income was -$6.0M. Diluted earnings per share stood at -$5.34. The company generated -$6.3M in operating cash flow. With a current ratio of 0.31, short-term liquidity bears monitoring.
Upcoming Events
ADPKD Phase 2 trial
Exaluren topline data
Topline data release
Final readout
Eloxx Pharmaceuticals has 4 upcoming scheduled events. The next event, "ADPKD Phase 2 trial", is scheduled for January 1, 2027 (in 110 days). Investors can track these dates to stay informed about potential catalysts that may affect the ELOX stock price.
Short Interest History
Short interest in Eloxx Pharmaceuticals (ELOX) currently stands at 24.4 thousand shares, up 47.4% from the previous reporting period, representing 0.8% of the float. Since September 2025, short interest has increased by 1089.6%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Eloxx Pharmaceuticals (ELOX) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 91.8% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
ELOX Company Profile & Sector Positioning
Eloxx Pharmaceuticals (ELOX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing ELOX often look at related companies in the same sector, including REGENERX BIOPHARMS INC (RGRX), NEXIMMUNE INC (NEXI), EFFECTOR THERAPUTCS INC (EFTR), GRITSTONE BIO INC (GRTSQ), and INNOVEREN SCIENTIFIC INC (IVRN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ELOX's relative position within its industry.